Compare Procter & Gamble Health with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs ORCHID PHARMA LTD - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH ORCHID PHARMA LTD PROCTER & GAMBLE HEALTH/
ORCHID PHARMA LTD
 
P/E (TTM) x 52.9 -0.5 - View Chart
P/BV x 4.8 0.1 4,067.2% View Chart
Dividend Yield % 9.9 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   ORCHID PHARMA LTD
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
ORCHID PHARMA LTD
Sep-13
PROCTER & GAMBLE HEALTH/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs3,549194 1,829.4%   
Low Rs1,30135 3,718.0%   
Sales per share (Unadj.) Rs511.4276.5 185.0%  
Earnings per share (Unadj.) Rs61.3-79.2 -77.4%  
Cash flow per share (Unadj.) Rs74.0-43.5 -170.3%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.853.9 1,720.1%  
Shares outstanding (eoy) m16.6070.45 23.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.70.4 1,144.9%   
Avg P/E ratio x39.6-1.4 -2,737.3%  
P/CF ratio (eoy) x32.8-2.6 -1,243.4%  
Price / Book Value ratio x2.62.1 123.1%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,2578,067 499.1%   
No. of employees `0001.12.8 40.5%   
Total wages/salary Rs m1,3132,527 51.9%   
Avg. sales/employee Rs Th7,486.76,956.1 107.6%   
Avg. wages/employee Rs Th1,157.6902.5 128.3%   
Avg. net profit/employee Rs Th897.2-1,993.0 -45.0%   
INCOME DATA
Net Sales Rs m8,49019,477 43.6%  
Other income Rs m244407 59.9%   
Total revenues Rs m8,73419,884 43.9%   
Gross profit Rs m1,4821,103 134.4%  
Depreciation Rs m2112,519 8.4%   
Interest Rs m05,227 0.0%   
Profit before tax Rs m1,514-6,236 -24.3%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m66511 12.8%   
Tax Rs m563-125 -449.3%   
Profit after tax Rs m1,017-5,580 -18.2%  
Gross profit margin %17.55.7 308.3%  
Effective tax rate %37.12.0 1,850.2%   
Net profit margin %12.0-28.7 -41.8%  
BALANCE SHEET DATA
Current assets Rs m15,34311,014 139.3%   
Current liabilities Rs m1,96032,060 6.1%   
Net working cap to sales %157.6-108.1 -145.9%  
Current ratio x7.80.3 2,278.4%  
Inventory Days Days4995 51.4%  
Debtors Days Days2834 84.8%  
Net fixed assets Rs m1,20929,440 4.1%   
Share capital Rs m166705 23.6%   
"Free" reserves Rs m15,2352,043 745.9%   
Net worth Rs m15,4013,800 405.3%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m17,59546,510 37.8%  
Interest coverage xNM-0.2-  
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.50.4 115.2%   
Return on assets %5.8-0.8 -760.8%  
Return on equity %6.6-146.9 -4.5%  
Return on capital %10.3-3.7 -274.7%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m1,6367,513 21.8%   
Fx outflow Rs m4,3685,649 77.3%   
Net fx Rs m-2,7321,865 -146.5%   
CASH FLOW
From Operations Rs m-1,3041,682 -77.5%  
From Investments Rs m12,697-9,860 -128.8%  
From Financial Activity Rs m-3016,644 -4.5%  
Net Cashflow Rs m11,093-1,535 -722.7%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 4.6 395.7%  
FIIs % 1.0 3.3 30.3%  
ADR/GDR % 0.0 4.6 -  
Free float % 29.1 55.3 52.6%  
Shareholders   28,591 84,811 33.7%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 17, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS